Cargando…
Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases
Latrepirdine (Dimebon(TM)) was originally marketed as a non-selective antihistamine in Russia. It was repurposed as an effective treatment for patients suffering from Alzheimer's disease (AD) and Huntington's disease (HD) following preliminary reports showing its neuroprotective functions...
Autores principales: | Bharadwaj, P R, Bates, K A, Porter, T, Teimouri, E, Perry, G, Steele, J W, Gandy, S, Groth, D, Martins, R N, Verdile, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030329/ https://www.ncbi.nlm.nih.gov/pubmed/24301650 http://dx.doi.org/10.1038/tp.2013.97 |
Ejemplares similares
-
The Effects of Latrepirdine on Amyloid-β Aggregation and Toxicity
por: Porter, Tenielle, et al.
Publicado: (2016) -
Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain
por: Steele, John W., et al.
Publicado: (2012) -
Acute dosing of latrepirdine (Dimebon™), a possible Alzheimer therapeutic, elevates extracellular amyloid-β levels in vitro and in vivo
por: Steele, John W, et al.
Publicado: (2009) -
Mitochondrial Pharmacology of Dimebon (Latrepirdine) Calls for a New Look at its Possible Therapeutic Potential in Alzheimer’s Disease
por: Eckert, Schamim H, et al.
Publicado: (2018) -
The Role of Presenilin and its Interacting Proteins in the Biogenesis of Alzheimer’s Beta Amyloid
por: Verdile, Giuseppe, et al.
Publicado: (2006)